Cucurbitacin A
CAS: 6040-19-3
Rif. 3D-GAA04019
| 10mg | Prezzo su richiesta | ||
| 25mg | Prezzo su richiesta | ||
| 50mg | Prezzo su richiesta |
Informazioni sul prodotto
- (2β,9β,10α,16α,23E)-25-(Acetyloxy)-2,16,20-trihydroxy-9-(hydroxymethyl)-19-norlanosta-5,23-diene-3,11,22-trione
- 19-Nor-9β,10α-lanosta-5,23-diene-3,11,22-trione, 2β,16α,20,25-tetrahydroxy-9-(hydroxymethyl)-, 25-acetate, (E)-
- 19-Norlanosta-5,23-diene-3,11,22-trione, 2,16,20,25-tetrahydroxy-9-(hydroxymethyl)-, 25-acetate
- 19-Norlanosta-5,23-diene-3,11,22-trione, 25-(acetyloxy)-2,16,20-trihydroxy-9-(hydroxymethyl)-, (2.beta.,9.beta.,10.alpha.,16.alpha.,23E)-
- 19-Norlanosta-5,23-diene-3,11,22-trione, 25-(acetyloxy)-2,16,20-trihydroxy-9-(hydroxymethyl)-, (2β,9β,10α,16α,23E)-
- Cucurbitacine A
- NSC 94743
Cucurbitacin A is a polyphenolic secondary metabolite that has been shown to have a variety of biological activities. It has been shown to inhibit HIV-1 replication and induce apoptosis in cancer cells. Cucurbitacin A also inhibits the growth of human prostate cancer cells by inhibiting the expression of proteins involved in cell proliferation, such as cyclin D1 and p27. Cucurbitacin A also has potent anticancer activity against a broad range of cancer cells including breast, lung, colon, leukemia, melanoma, and ovarian cancers. Moreover, cucurbitacin A shows promise for the treatment of heart disease because it has been shown to inhibit platelet aggregation. The chemical stability and chemical composition make cucurbitacin A an attractive candidate for use as a pharmaceutical preparation.
Proprietà chimiche
Richiesta tecnica su: 3D-GAA04019 Cucurbitacin A
Se si desidera richiedere un preventivo o effettuare un ordine, si prega invece di aggiungere i prodotti desiderati al carrello e poi richiedere un preventivo o un ordine dal carrello. È più veloce, più economico, e potrà beneficiare degli sconti disponibili e di altri vantaggi.
